Clinical Practice Guideline

Pharmacological Management of Osteoporosis in Postmenopausal Women Guideline Resources

February 17, 2020

Full Guideline: Pharmacological Management of Osteoporosis in Postmenopausal Women
JCEM: May 2019 (online March 2019)

Richard Eastell, Clifford J. Rosen (chair), Dennis M. Black, Angela M. Cheung, M. Hassan Murad, and Dolores Shoback

Guideline Update: Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update
JCEM: March 2020 (online February 2020)

Dolores Shoback, Clifford J. Rosen (chair), Dennis M. Black, Angela M. Cheung, M. Hassan Murad, and Richard Eastell

The guideline on pharmacological management of osteoporosis in postmenopausal women:

  • Provides recommendations for the treatment and management of osteoporosis in postmenopausal women
  • Emphasizes assessment after being on treatments to see if further treatment is necessary


Resources

Guideline Introduction | ENDO 2019


Essential Points

  • Treat high risk individuals - particularly those with previous fracture.
  • Consider bisphosphonates as the first line therapeutic choice for postmenopausal women at high risk of fracture.
  • Reassess fracture risk after patient has been on bisphosphonates for 3-5 years.
  • Following reassessment, prescribe a “bisphosphonate holiday” for women who are on bisphosphonates and are low-to-moderate risk of fracture.
  • Consider anabolic therapy (teriparatide or abaloparatide) for women at very high risk of fractures, including those with multiple fractures.
  • All women undergoing treatment with osteoporosis therapies other than anabolic therapy should consume calcium and vitamin D in their diet or via supplements.
  • Monitor the BMD of high-risk individuals with a low BMD every 1 to 3 years.

List of Recommendations

+ 1.0 Who to Treat

+ 2.0 Bisphosphonates

+ 3.0 Denosumab

+ 4.0 Teriparatide and Abaloparatide—Parathyroid Hormone and Parathyroid Hormone-Related Protein (PTHrP) Analogs

+ Update A (2020). Romosozumab

+ 5.0 Selective Estrogen Receptor Modulators

+ 6.0 Menopausal Hormone Therapy and Tibolone

+ 7.0 Calcitonin

+ 8.0 Calcium and Vitamin D

+ 11.0 Monitoring

Clinical Practice Guidelines

CPG Pocket Guides

Clinical Practice Guidelines Pocket Guides
Practical quick-reference tools to help you make accurate clinical decisions at the point of care.
Clinical Practice Guidelines

CPG Pocket Guides

Practical quick-reference tools to help you make accurate clinical decisions at the point of care.

CPG Mobile App

Access guideline recommendations, patient information, and clinical education modules for a range of endocrine topics plus dozens of interactive decision algorithms and other point-of-care tools.

Download our CPG Mobile App

Access guideline recommendations, patient information, and clinical education modules for a range of endocrine topics plus dozens of interactive decision algorithms and other point-of-care tools.

Back to top

Who We Are

For 100 years, the Endocrine Society has been at the forefront of hormone science and public health. Read about our history and how we continue to serve the endocrine community.